Boston Scientific stock holds steady as analysts weigh cyberattack impact
Published on 09/20/2026 at 11:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Boston Scientific Corporation stock (ISIN US10117L1017) last closed at USD 43.41 on the New York Stock Exchange on September 18, 2026, leaving a wide gap to the consensus analyst price target of USD 71.04.
Analysts reassess Boston Scientific after cyberattack
According to MarketBeat on September 18, 2026, Boston Scientific carries a consensus rating of Moderate Buy, based on 23 buy, 6 hold and 2 sell recommendations.
The same overview shows an average price target of USD 71.04, implying about 63.6% upside from the September 18, 2026 closing price of USD 43.41, with individual targets ranging from USD 50.00 to USD 118.00.
Analyst headlines compiled by MarketBeat note that one house recently maintained a Buy rating while trimming near term forecasts after a cyberattack, while Citi downgraded the stock citing increasing competition and the same incident as a risk factor.
Latest price, valuation and trading metrics
Per data from Yahoo Finance, Boston Scientific shares traded at USD 43.34 at the regular close on September 18, 2026, down 0.48% on the day, before edging up to USD 43.53 in after hours trading.
The same snapshot lists a 52-week low of USD 42.20 and a 52-week high of USD 105.65, meaning the September 18, 2026 close sits just above the low and far below the top of the yearly range.
According to MarketBeat, Boston Scientific had a market capitalization of about USD 62.91 billion with a trailing price-earnings ratio of 17.57 as of the September 18, 2026 close, on trading volume of 29.24 million shares versus an average of 21.14 million.
Fundamental backdrop and valuation narrative
The analyst overview on MarketBeat highlights trailing twelve month earnings per share for Boston Scientific, which helps underpin the current price-earnings multiple of 17.57.
A separate valuation narrative on Simply Wall St argues that Boston Scientific could be trading at a discount to intrinsic value based on its cash flows and track record, describing the shares as potentially 56% undervalued relative to a fair value estimate.
For investors, the combination of a consensus Moderate Buy rating, an implied 63.6% upside to the average price target and an independent view of possible undervaluation sets the stage for a classic risk-reward debate around the stock.
Risks from competition and cyberattack fallout
Analyst news collated by MarketBeat references a downgrade from Citi, which points to intensifying competition in Boston Scientific's markets and lingering effects from a cyberattack as key factors behind a more cautious stance.
At the same time, another analyst cited in the headlines maintains a Buy rating and views the cyberattack impact as short lived, even while trimming near term forecasts to reflect disruption, indicating that the sell side remains divided on the severity of the event.
This mix of concern about operational risks and confidence in the longer term trajectory helps explain why Boston Scientific stock currently trades near the lower end of its 52-week range despite relatively supportive consensus targets.
Stock price level as of the last trading day
Boston Scientific stock finished regular trading on the New York Stock Exchange at USD 43.34 on September 18, 2026, before modestly rebounding to USD 43.53 in extended trading, keeping the shares just above their 52-week low of USD 42.20 and far below the 52-week high of USD 105.65.
Boston Scientific stock - key data
- Company: Boston Scientific Corporation
- ISIN: US10117L1017
- Ticker: BSX
- Trading venue: NYSE
- Price (as of September 18, 2026, 04:00): 43.34 USD
- Market capitalization: 62.91 billion USD (as of September 18, 2026)
- Sector / Industry: Health Care / Medical Devices
- Index membership: S&P 500
